Technology
Cell Viable compounds modify skin collagen as anti glycation, anti inflammatory and anti oxidation agents.
All of the preliminary screening of the compounds for anti-glycation activity and in vitro toxicity were carried out in the laboratory of Dr. Diana Casper at the Montefiore Hospital (Research Center) at Albert Einstein University in New York. They were also tested at the Montefiore Hospital for purity.
Currently we are working with a company in France to manufacture the compounds to complete toxicology and formulation studies. Componding and clinical trials will be carried out in France in 2020.